Introduction

Tirzepatide is a dual GLP-1 and GIP receptor agonist peptide studied for its effects on glucose control, weight regulation, and metabolic health.¹ Like other incretin-based peptides, tirzepatide research shows dose-dependent gastrointestinal effects along with potential cardiometabolic benefits.²

This article reviews tirzepatide side effects reported in research, distinguishing between common, less common, and rare but serious events.

For research use only — not for human consumption.

Common Side Effects

These are the most frequently observed in clinical trials, particularly during dose escalation:

• Nausea (up to 20–30% of participants)³
  
• Vomiting
  
• Diarrhea
  
• Constipation
  
• Decreased appetite⁴

Why this matters: GI effects are usually transient and dose-dependent, peaking during titration and declining over time.

Less Common Side Effects

• Injection-site reactions (mild erythema, swelling)⁵
  
• Headache and dizziness
  
• Mild hypoglycemia (particularly when combined with insulin or sulfonylureas)⁶

Rare or Serious Adverse Effects

Although rare, certain effects require further study:

• Pancreatitis: Cases have been reported, as with GLP-1 agonists.⁷
  
• Gallbladder disease: Higher incidence of gallstones in some participants.⁸
  
• Diabetic retinopathy worsening: Observed in GLP-1 agonist class; relevance to tirzepatide under investigation.⁹
  
• Potential oncology signals: Rodent studies raised thyroid tumor concerns, but human significance is unclear.¹⁰are when used alone, but more likely when combined with insulin or sulfonylureas.⁹
  

Safety Profile in Research

• Cardiometabolic safety: Early studies suggest benefits for lipids, blood pressure, and inflammatory markers.¹¹
  
• Tolerance strategies: Slow titration helps mitigate GI side effects.³
  
• Limitations: Most safety data comes from type 2 diabetes and obesity trials; long-term outcomes are still under investigation

Summary

Tirzepatide’s side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are dose-dependent and often transient. Less common side effects include mild hypoglycemia and injection-site reactions, while rare risks such as pancreatitis and gallbladder disease remain under investigation.

FAQs About Tirzepatide Side Effects

Related Articles

• What is Tirzepatide
• How Does Tirzepatide Work
• Tirzepatide Benefits
• Semaglutide vs Tirzepatide vs Retatrutide
• Semaglutide Side Effects & Safety
• Retatrutide Side Effects & Safety

References

1. Coskun T, et al. LY3298176 (tirzepatide), a dual GIP and GLP-1 receptor agonist. Sci Transl Med. 2018;10(467):eaao7796. https://pubmed.ncbi.nlm.nih.gov/29954859/
   
2. Drucker DJ. Mechanisms of incretin hormones. Cell Metab. 2018;27(4):740–756. https://pubmed.ncbi.nlm.nih.gov/29617643/
   
3. Frias JP, et al. Tirzepatide vs semaglutide in type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503–515. https://pubmed.ncbi.nlm.nih.gov/34170647/
   
4. Jastreboff AM, et al. Tirzepatide in obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
   
5. Urva S, et al. Clinical pharmacology of tirzepatide. Clin Pharmacokinet. 2022;61(3):365–379. https://pubmed.ncbi.nlm.nih.gov/34888505/
   
6. Rosenstock J, et al. Tirzepatide in type 2 diabetes. Lancet. 2019;394(10193):141–151. https://pubmed.ncbi.nlm.nih.gov/31235408/
   
7. Drucker DJ, Nauck MA. GLP-1 receptor agonists and pancreatitis risk. Diabetes Care. 2016;39(2):210–218. https://pubmed.ncbi.nlm.nih.gov/26798109/
   
8. Smits MM, et al. GLP-1–based therapies and gallbladder risk. Diabetes Metab Res Rev. 2016;32(3):323–335. https://pubmed.ncbi.nlm.nih.gov/26418027/
   
9. Marso SP, et al. GLP-1 agonists and diabetic retinopathy risk. N Engl J Med. 2016;375(4):311–322. https://pubmed.ncbi.nlm.nih.gov/27295427/
   
10. Nauck MA, et al. Safety of incretin-based therapies. Diabetes Obes Metab. 2017;19(3):279–291. https://pubmed.ncbi.nlm.nih.gov/27809397/
    
11. Ludvik B, et al. Tirzepatide cardiometabolic benefits. Diabetes Care. 2021;44(11):2776–2784. https://pubmed.ncbi.nlm.nih.gov/34321332/